Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.2
2.7
Journals
Diabetology
Special Issues
Osteoporosis and Fracture Risk in Diabetes: Updated Clinical, Hormonal and...
share announcement

Osteoporosis and Fracture Risk in Diabetes: Updated Clinical, Hormonal and Molecular Insights

A special issue of Diabetology (ISSN 2673-4540).

Deadline for manuscript submissions: closed (31 March 2026) | Viewed by 5177

Editor

Dr. Mara Carsote

E-Mail Website
Guest Editor
1. Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
2. Department of Endocrinology, C.I. Parhon National Institute of Endocrinology, 011863 Bucharest, Romania
Interests: thyroid; adrenal; pituitary; osteoporosis; neuroendocrine tumors; bone; fracture; gynecological endocrinology; diabetes
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We invite you to contribute to one or multiple articles, either an original study, an updated review (systematic or narrative) or other types of analyses, regarding the complex landscape of bone and related muscle involvement in diabetes mellitus type 1 or 2 or secondary diabetes, as found in various endocrine and non-endocrine conditions such as functioning adrenal tumors, neoplasia-related excess of pituitary hormones, pancreatic anomalies, parathyroid tumors, and corticotherapy.

We are particularly interested (but not exclusively) in the following domains/cross-domains or trans-disciplinary approaches:

  • Traditional and new tools to estimate the fracture risk in various diabetic subpopulations;
  • Anti-fracture intervention from standard drug regime to novel agents (antiresorptive or osteoanabolic) in individuals confirmed with diabetes;
  • The fracture risk which is correlated with using new classes of medication against diabetes and obesity (current level of statistical evidence, controversies, pitfalls);
  • Biomarkers of bone and muscle involvement in various diabetic subgroups (myokines, adipokines, inflammatory markers, bone resorption markers, bone formation markers, etc.);
  • Rehabilitation, fracture healing and non-pharmacologic intervention for primary and secondary fracture prevention in diabetic subjects;
  • New pathogenic loops in the bone-muscle-fat-gut cross-talk.

Dr. Mara Carsote
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diabetology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes mellitus
  • endocrine
  • hormone, bone
  • fracture
  • fracture risk assessment
  • skeleton
  • fracture healing
  • anti-osteoporotic drugs
  • osteoanabolic agents
  • FRAX
  • FRAXplus
  • bone turnover markers
  • mineral metabolism
  • DXA
  • osteoporosis
  • osteopenia
  • secondary diabetes
  • osteocalcin
  • muscle
  • irisin
  • collagen

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 473 KB  
Article
Circulating Irisin as a Possible Marker of Glucose and Bone Metabolism: Evidence from the IRI-OP-OB Pilot Study
by Veronica Cumpata, Ana-Maria Gheorghe, Luminita Suveica, Oana-Claudia Sima, Natalia Loghin-Oprea, Mihai Costachescu, Eugenia Petrova, Alexandra-Ioana Trandafir, Ana Popescu, Dana Manda, Sorina Violeta Schipor and Mara Carsote
Diabetology 2026, 7(2), 23; https://doi.org/10.3390/diabetology7020023 - 29 Jan 2026
Viewed by 965
Abstract
Background: Irisin, a recently discovered muscle-originating hormone, has been found to act as a biomarker of several ailments, while no guideline clearly indicates its testing so far in any particular population category or pathological condition. Objective: We analyzed blood (circulating) irisin [...] Read more.
Background: Irisin, a recently discovered muscle-originating hormone, has been found to act as a biomarker of several ailments, while no guideline clearly indicates its testing so far in any particular population category or pathological condition. Objective: We analyzed blood (circulating) irisin in relation to the potential correlations with the evaluation of glucose and bone profile. Methods: This was a prospective, pilot, exploratory study (between December 2024 and August 2025). The enrolled patients were menopausal women aged ≥50. Exclusion criteria: Endocrine tumors, thyroid dysfunction, malignancies, or chronic kidney disease. Baseline (fasting) testing was followed by 75 g oral glucose tolerance test (OGTT). Enzyme-linked immunosorbent assay (ELISA)-based irisin assay (MyBioSource) was performed. The subjects underwent central Dual-Energy X-Ray Absorptiometry (DXA), which provided lumbar, femoral neck and total hip bone mineral density (BMD)/T-score (GE Lunar Prodigy), and lumbar DXA-based trabecular bone score (TBS iNsight). Results: We enrolled 89 females [mean age of 62.84 ± 9.33 years, average years since menopause (YSM) of 15.94 ± 9.23]. Irisin (102.69 ± 98.14 ng/mL) did not correlate with age, YSM, but with body mass index (r = 0.36, p < 0.001). Bone formation marker osteocalcin (r = −0.25, p = 0.018) was negatively associated with irisin, amidst multiple other mineral metabolism assays (including PTH and 25-hydroxyvitamin D). Irisin positively correlated with insulin (r = 0.385, p = 0.0008), HbA1c (r = 0.243, p = 0.022), and HOMA-IR (r = 0.313, p = 0.007). Additional endocrine assays pointed a statistically significant association between irisin and TSH, respectively, ACTH (r = 0.267, p = 0.01, and r = 0.309, p = 0.041, respectively). No correlation irisin-BMD/T-score/TBS was confirmed. Conclusions: Irisin correlates with markers of glucose status (insulin, HOMA-IR, and HbA1c), as well as body mass index and, to a lesser extent, bone metabolism markers. Interestingly, TSH and ACTH correlations open a new (hypothesis-generating) perspective in the endocrine frame of approaching this exerkine. To the best of our knowledge, no distinct study has so far addressed the TBS–irisin relationship or pinpointed the glucose effects on TBS, particularly in menopausal women. Full article
(This article belongs to the Special Issue Osteoporosis and Fracture Risk in Diabetes: Updated Clinical, Hormonal and Molecular Insights)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

19 pages, 618 KB  
Review
Diabetic Bone Disease: A Comprehensive Narrative Review of Pathophysiology, Diagnosis, and Evidence-Based Management
by João Protásio Netto, Vagner Camargo Pires and Mariana Garcia Martins Castro
Diabetology 2025, 6(11), 140; https://doi.org/10.3390/diabetology6110140 - 11 Nov 2025
Cited by 3 | Viewed by 3656
Abstract
Background: Diabetic bone disease affects over 537 million people with diabetes worldwide, characterized by increased fracture risk despite paradoxically normal or elevated bone mineral density (BMD) in Type 2 diabetes. This narrative review synthesizes current evidence on pathophysiology, diagnostic approaches, and management [...] Read more.
Background: Diabetic bone disease affects over 537 million people with diabetes worldwide, characterized by increased fracture risk despite paradoxically normal or elevated bone mineral density (BMD) in Type 2 diabetes. This narrative review synthesizes current evidence on pathophysiology, diagnostic approaches, and management strategies. Methods: We performed a comprehensive literature search of the PubMed, Embase, and Cochrane databases (2007–2025), prioritizing systematic reviews, meta-analyses, large-scale population studies, and clinical trials examining bone health in diabetes, including bone density, quality, fracture risk, imaging techniques, biomarkers, and therapeutic interventions. Results: Advanced glycation end products fundamentally alter bone metabolism through mechanisms distinct from traditional osteoporosis. Type 1 and Type 2 diabetes produce contrasting skeletal phenotypes requiring tailored management. Recent umbrella reviews of 71 meta-analyses demonstrated skeletal benefits of metformin and GLP-1 receptor agonists, while confirming thiazolidinedione risks. Trabecular bone score enhances fracture prediction when DXA appears normal. Large-scale studies revealed heterogeneous risk patterns, with specific subgroups showing substantially elevated fracture risk. Advanced imaging revealed distinct microarchitectural changes between diabetes types. Diabetic patients experienced doubled healing complications, necessitating specialized perioperative protocols. Conclusions: Diabetic bone disease represents a distinct clinical entity requiring enhanced diagnostic strategies beyond traditional densitometry, evidence-based treatment selection considering skeletal and metabolic effects, and specialized management protocols extending beyond conventional osteoporosis care. Full article
(This article belongs to the Special Issue Osteoporosis and Fracture Risk in Diabetes: Updated Clinical, Hormonal and Molecular Insights)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop